EZH2 and non-small cell lung carcinoma: EZH2 has been implicated in the sensitivity/resistance to TOP2 poisons; NSCLC cell lines have demonstrated enhanced sensitivity to EZH2 inhibition with etoposide therapy both in vitro and in vivo (47).